Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
The EndRAD Trial: Eliminating Total Body Irradiation TBI for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
Study Type: Treatment
Phase: II
NCTID: NCT03509961
Principal Investigator:
Ibrahim Ahmed
Long-Term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated with Gene-Modified Cells
Study Type: Treatment
Phase: IV
NCTID: NCT05041309
Principal Investigator:
Nausheen Ahmed
A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation versus Conventional Care in Older Subjects with Active, Relapsed or Refractory Acute Myeloid Leukemia.
AUGMENT-102: A Phase 1, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability and Preliminary Anti-Leukemic Activity of SNDX-5613 in Combination with Chemotherapy in Patients with Relapsed/ Refractory Leukemias Harboring a KMT2A/MLL Gene Rearrangement or Nucleophosmin 1 Mutation mNPM1
Study Type: Treatment
Phase: I
NCTID: NCT05326516
Principal Investigator:
Kevin Ginn
The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Study Type: Other
Phase: N/A
NCTID: NCT02402244
Principal Investigator:
Keith August
A Phase IB/IIA, Open-Label Study Of The Safety, Pharmacokinetics, And Pharmacodynamics Of Fosciclopirox Alone And In Combination With Cytarabine In Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan GMI-1271 in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Phase I study of venetoclax/azacitidine or venetoclax in combination with ziftomenib KO-539 or standard induction cytarabine/daunorubicin 7+3 chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia
Inotuzumab Ozogamicin Post-Transplant for Acute Lymphocytic Leukemia and Non-Hodgkin?s Lymphoma
Study Type: Treatment
Phase: I
NCTID: NCT03104491
Principal Investigator:
Nausheen Ahmed